Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: shaanxi who wrote (772)	8/25/1998 1:23:00 AM
From: FNS	Read Replies (1) \| Respond to of 965

More like 6 points within the last week! The stock may be playing a different tune this time....rising slower on pending and announced good news. Now let's hope it holds....but won't be disappointed if it sells off to 37 (and a good buy imho). Hopefully the stock will grind through the 40 area.....then 43-44 area will be another hurdle. CNTO has 'delivered', so now the stock will have to react to projected data...and then to the reality of the QTRLY earnings. Any thoughts on how much expense/writeoff (10k) will be incurred to do the Avakine direct distribution??? When can a payoff be expected??? Looks like CNTO has succeeded as a biotech company with Reopro and a first for Crohn's disease...now lets see how they play out as a business machine! Still, $52 or $65 in another year is ok. Regardless, the real winners are the cardiac and crohns patients. Good luck to all. FNS